Abstract | OBJECTIVE: DESIGN: Single-center observational study with a historical control group. SETTING: University clinic. PATIENTS: INTERVENTIONS: In 16 consecutive patients (2005-2006), MTH was initiated immediately after admission and continued during primary PCI. Seventeen consecutive patients who were treated in a similar 2-yr observation interval before implementation of MTH (2003-2004) served as a control group. Feasibility, safety, mortality, and neurologic outcome were documented. MEASUREMENTS AND MAIN RESULTS: Initiation of MTH did not result in longer door-to-balloon times compared with the control group (82 vs. 85 mins), indicating that implementation of MTH did not delay the onset of primary PCI. Target temperature (32-34 degrees C) in the MTH group was reached within 4 hrs, consistent with previous trials and suggesting that primary PCI did not affect the velocity of cooling. Despite a tendency to increased bleeding complications and infections, patients treated with MTH tended to have a lower mortality after 6 months (25% vs. 35%, p = .71) and an improved neurologic outcome as determined by a Glasgow-Pittsburgh Cerebral Performance Scale score of 1 or 2 (69% vs. 47% in the control group, p = .30). CONCLUSIONS:
|
Authors | Sebastian Wolfrum, Christian Pierau, Peter W Radke, Heribert Schunkert, Volkhard Kurowski |
Journal | Critical care medicine
(Crit Care Med)
Vol. 36
Issue 6
Pg. 1780-6
(Jun 2008)
ISSN: 1530-0293 [Electronic] United States |
PMID | 18496378
(Publication Type: Journal Article)
|
Topics |
- Aged
- Angioplasty, Balloon, Coronary
- Cardiopulmonary Resuscitation
(methods)
- Critical Pathways
- Electrocardiography
- Emergency Medical Services
- Feasibility Studies
- Female
- Follow-Up Studies
- Germany
- Heart Arrest
(mortality, therapy)
- Humans
- Hypothermia, Induced
(methods)
- Intensive Care Units
(statistics & numerical data)
- Male
- Middle Aged
- Myocardial Infarction
(mortality, therapy)
- Neurologic Examination
- Outcome and Process Assessment, Health Care
- Prospective Studies
- Survival Rate
- Time and Motion Studies
- Ventricular Fibrillation
(mortality, therapy)
|